Literature DB >> 18582447

Stimulation of the alpha4beta2 nicotinic receptor by 5-I A-85380 improves auditory gating in DBA/2 mice.

Kristin M Wildeboer1, Karen E Stevens.   

Abstract

Abnormal auditory gating is a symptom of schizophrenia which has been proposed to be mediated through the alpha7 nicotinic acetylcholine receptor (nAChR). It has been shown that the non-selective nicotinic agonist nicotine has an influence on auditory gating in part by acting on the alpha4beta2 nAChR. The goal of this study was to determine the effect of 5-I A-85380, an agonist for the alpha4beta2 nAChR, in an inbred mouse model with a deficiency for auditory gating. Anesthetized DBA/2 mice were administered 5-I A-85380 alone and in combination with the alpha4beta2 nAChR antagonist, dihydro-beta-erythroidine, or the alpha7 nAChR antagonist, alpha-bungarotoxin. A recording electrode in the CA3 region of the hippocampus recorded P20-N40 waveforms in response to two auditory stimuli. The amplitudes of the response to the first and second clicks were used to determine TC ratios, the measure of auditory gating. 5-I A-85380 significantly decreased the TC ratios by selectively increasing the response amplitudes to the first click with no significant influence on the response amplitudes to the second click. The effect was blocked by dihydro-beta-erythroidine whereas alpha-bungarotoxin had no effect on response amplitude to either click. Although the alpha7 nAChR may mediate the hippocampal response of DBA/2 mice to the second click, the alpha4beta2 nAChR appears to modulate the response to the first click. Thus, the present study implicates the involvement of more than one subtype of nAChR in the auditory gating of DBA/2 mice, specifically the alpha4beta2 nAChR, and its role in the response amplitude to the first stimulus.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18582447      PMCID: PMC2596929          DOI: 10.1016/j.brainres.2008.06.007

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  50 in total

1.  Genetic correlation of inhibitory gating of hippocampal auditory evoked response and alpha-bungarotoxin-binding nicotinic cholinergic receptors in inbred mouse strains.

Authors:  K E Stevens; R Freedman; A C Collins; M Hall; S Leonard; M J Marks; G M Rose
Journal:  Neuropsychopharmacology       Date:  1996-08       Impact factor: 7.853

2.  Restoration of sensory gating of auditory evoked response by nicotine in fimbria-fornix lesioned rats.

Authors:  P C Bickford; K D Wear
Journal:  Brain Res       Date:  1995-12-24       Impact factor: 3.252

3.  Activation and inhibition of rat neuronal nicotinic receptors by ABT-418.

Authors:  R L Papke; J S Thinschmidt; B A Moulton; E M Meyer; A Poirier
Journal:  Br J Pharmacol       Date:  1997-02       Impact factor: 8.739

4.  Determinants of competitive antagonist sensitivity on neuronal nicotinic receptor beta subunits.

Authors:  S C Harvey; C W Luetje
Journal:  J Neurosci       Date:  1996-06-15       Impact factor: 6.167

5.  Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus.

Authors:  R Freedman; H Coon; M Myles-Worsley; A Orr-Urtreger; A Olincy; A Davis; M Polymeropoulos; J Holik; J Hopkins; M Hoff; J Rosenthal; M C Waldo; F Reimherr; P Wender; J Yaw; D A Young; C R Breese; C Adams; D Patterson; L E Adler; L Kruglyak; S Leonard; W Byerley
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-21       Impact factor: 11.205

6.  Molecular cloning and chromosomal localization of the human alpha 7-nicotinic receptor subunit gene (CHRNA7).

Authors:  B Chini; E Raimond; A B Elgoyhen; D Moralli; M Balzaretti; S Heinemann
Journal:  Genomics       Date:  1994-01-15       Impact factor: 5.736

7.  Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia.

Authors:  R Freedman; M Hall; L E Adler; S Leonard
Journal:  Biol Psychiatry       Date:  1995-07-01       Impact factor: 13.382

8.  Cloning and mapping of the mouse alpha 7-neuronal nicotinic acetylcholine receptor.

Authors:  A Orr-Urtreger; M F Seldin; A Baldini; A L Beaudet
Journal:  Genomics       Date:  1995-03-20       Impact factor: 5.736

9.  (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization.

Authors:  S P Arneric; J P Sullivan; C A Briggs; D Donnelly-Roberts; D J Anderson; J L Raszkiewicz; M L Hughes; E D Cadman; P Adams; D S Garvey
Journal:  J Pharmacol Exp Ther       Date:  1994-07       Impact factor: 4.030

10.  Human alpha 7 nicotinic acetylcholine receptor responses to novel ligands.

Authors:  C A Briggs; D G McKenna; M Piattoni-Kaplan
Journal:  Neuropharmacology       Date:  1995-06       Impact factor: 5.250

View more
  10 in total

1.  Severe cross-modal object recognition deficits in rats treated sub-chronically with NMDA receptor antagonists are reversed by systemic nicotine: implications for abnormal multisensory integration in schizophrenia.

Authors:  Derek L Jacklin; Amit Goel; Kyle J Clementino; Alexander W M Hall; John C Talpos; Boyer D Winters
Journal:  Neuropsychopharmacology       Date:  2012-06-06       Impact factor: 7.853

Review 2.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

3.  Continuous administration of a selective alpha7 nicotinic partial agonist, DMXBA, improves sensory inhibition without causing tachyphylaxis or receptor upregulation in DBA/2 mice.

Authors:  Karen E Stevens; Brandon Cornejo; Catherine E Adams; Lijun Zheng; Joan Yonchek; Keith L Hoffman; Uwe Christians; William R Kem
Journal:  Brain Res       Date:  2010-07-03       Impact factor: 3.252

4.  Maximizing the effect of an α7 nicotinic receptor PAM in a mouse model of schizophrenia-like sensory inhibition deficits.

Authors:  Karen E Stevens; Lijun Zheng; Kirsten L Floyd; Jerry A Stitzel
Journal:  Brain Res       Date:  2015-03-02       Impact factor: 3.252

5.  The smoking cessation drug varenicline improves deficient P20-N40 inhibition in DBA/2 mice.

Authors:  Kristin M Wildeboer-Andrud; Karen E Stevens
Journal:  Pharmacol Biochem Behav       Date:  2011-07-07       Impact factor: 3.533

6.  Antidepressants may mitigate the effects of prenatal maternal anxiety on infant auditory sensory gating.

Authors:  Sharon K Hunter; Jordan H Mendoza; Kimberly D'Anna; Gary O Zerbe; Lizbeth McCarthy; Camille Hoffman; Robert Freedman; Randal G Ross
Journal:  Am J Psychiatry       Date:  2012-06       Impact factor: 18.112

7.  Cotinine impacts sensory processing in DBA/2 mice through changes in the conditioning amplitude.

Authors:  Kristin M Wildeboer-Andrud; Lijun Zheng; Kevin S Choo; Karen E Stevens
Journal:  Pharmacol Biochem Behav       Date:  2013-12-26       Impact factor: 3.533

8.  Ondansetron results in improved auditory gating in DBA/2 mice through a cholinergic mechanism.

Authors:  Kristin M Wildeboer; Lijun Zheng; Kevin S Choo; Karen E Stevens
Journal:  Brain Res       Date:  2009-09-01       Impact factor: 3.252

9.  The nicotinic acetylcholine receptor alpha 4 subunit contains a functionally relevant SNP Haplotype.

Authors:  Marlene Eggert; Georg Winterer; Mario Wanischeck; Jean-Charles Hoda; Daniel Bertrand; Ortrud Steinlein
Journal:  BMC Genet       Date:  2015-05-02       Impact factor: 2.797

10.  Nicotine receptor subtype-specific effects on auditory evoked oscillations and potentials.

Authors:  Robert E Featherstone; Jennifer M Phillips; Tony Thieu; Richard S Ehrlichman; Tobias B Halene; Steven C Leiser; Edward Christian; Edwin Johnson; Caryn Lerman; Steven J Siegel
Journal:  PLoS One       Date:  2012-07-20       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.